[go: up one dir, main page]

MX2012003759A - Metodos y composiciones para tratamiento de fibrosis ocular. - Google Patents

Metodos y composiciones para tratamiento de fibrosis ocular.

Info

Publication number
MX2012003759A
MX2012003759A MX2012003759A MX2012003759A MX2012003759A MX 2012003759 A MX2012003759 A MX 2012003759A MX 2012003759 A MX2012003759 A MX 2012003759A MX 2012003759 A MX2012003759 A MX 2012003759A MX 2012003759 A MX2012003759 A MX 2012003759A
Authority
MX
Mexico
Prior art keywords
methods
treatment
compositions
ocular fibrosis
modulators
Prior art date
Application number
MX2012003759A
Other languages
English (en)
Inventor
Victoria Smith
Ingeborg Stalmans
Tine Van Bergen
Original Assignee
Gilead Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Biologics Inc filed Critical Gilead Biologics Inc
Publication of MX2012003759A publication Critical patent/MX2012003759A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se dan a conocer en este documento métodos y composiciones para el tratamiento de fibrosis ocular, como ocurre por ejemplo durante el tratamiento de glaucoma mediante trabeculectomía. Las composiciones comprenden moduladores de la actividad de una o más enzimas de tipo lisil oxidasa (por ejemplo, LOX, LOXL2), y los métodos incluyen métodos para hacer los moduladores y métodos para la administración de los moduladores a un sujeto en necesidad de la misma.
MX2012003759A 2009-09-29 2010-09-28 Metodos y composiciones para tratamiento de fibrosis ocular. MX2012003759A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27791809P 2009-09-29 2009-09-29
US39745610P 2010-06-11 2010-06-11
PCT/US2010/050542 WO2011041309A1 (en) 2009-09-29 2010-09-28 Methods and compositions for treatment of ocular fibrosis

Publications (1)

Publication Number Publication Date
MX2012003759A true MX2012003759A (es) 2012-07-23

Family

ID=43780639

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003759A MX2012003759A (es) 2009-09-29 2010-09-28 Metodos y composiciones para tratamiento de fibrosis ocular.

Country Status (11)

Country Link
US (1) US20110076285A1 (es)
EP (1) EP2482814A4 (es)
JP (1) JP2013506005A (es)
KR (1) KR20120091146A (es)
CN (1) CN102711753A (es)
AU (1) AU2010300813A1 (es)
BR (1) BR112012007114A2 (es)
CA (1) CA2775877A1 (es)
MX (1) MX2012003759A (es)
RU (1) RU2012117896A (es)
WO (1) WO2011041309A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
DK2185198T3 (en) 2007-08-02 2015-04-20 Gilead Biologics Inc LOX AND LOXL2 INHIBITORS AND APPLICATIONS THEREOF
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
AU2010210489A1 (en) * 2009-02-06 2011-08-25 Gilead Biologics, Inc. Methods and compositions for treatment of neovascularization
SG2014004816A (en) * 2009-08-21 2014-03-28 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
EP2470218A4 (en) * 2009-08-21 2013-04-03 Gilead Biologics Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROGEN DISORDERS
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
CN102711821A (zh) * 2009-08-21 2012-10-03 吉联亚生物科技有限公司 治疗方法和组合物
SG183174A1 (en) * 2010-02-04 2012-09-27 Gilead Biologics Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
KR20250026890A (ko) 2016-03-08 2025-02-25 유니버시티 오브 유타 리서치 파운데이션 가교-결합제 및 관련 방법
EP3503928A4 (en) * 2016-08-19 2020-03-18 Colorado State University Research Foundation METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANINE CONDITIONS USING A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS.
KR20230130155A (ko) 2016-08-19 2023-09-11 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
EP3551650A4 (en) 2016-12-07 2020-07-08 The University of Florida Research Foundation Incorporated IL-1RA ADNC
US20210002641A1 (en) * 2018-03-16 2021-01-07 The Regents Of The University Of Michigan Compositions and methods for treating graves disease
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
KR20200030875A (ko) 2018-09-13 2020-03-23 전남대학교산학협력단 트리코스타틴 a를 유효성분으로 포함하는 결막 섬유화 억제용 약학적 조성물
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
GB202209624D0 (en) 2022-06-30 2022-08-17 Institute Of Cancer Res Royal Cancer Hospital Prodrugs
GB202209622D0 (en) 2022-06-30 2022-08-17 Institute Of Cancer Res Royal Cancer Hospital Compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300092B1 (en) * 1999-01-27 2001-10-09 Millennium Pharmaceuticals Inc. Methods of use of a novel lysyl oxidase-related protein
US20030152926A1 (en) * 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20060134172A1 (en) * 2004-12-21 2006-06-22 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US20070021365A1 (en) * 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
IL184627A0 (en) * 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
DK2185198T3 (en) * 2007-08-02 2015-04-20 Gilead Biologics Inc LOX AND LOXL2 INHIBITORS AND APPLICATIONS THEREOF
US8815946B2 (en) * 2008-01-25 2014-08-26 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of proliferation and fibrotic response of activated corneal stromal cells
WO2010080769A2 (en) * 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
AU2010210489A1 (en) * 2009-02-06 2011-08-25 Gilead Biologics, Inc. Methods and compositions for treatment of neovascularization
SG2014004816A (en) * 2009-08-21 2014-03-28 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
EP2470218A4 (en) * 2009-08-21 2013-04-03 Gilead Biologics Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROGEN DISORDERS
CN102711821A (zh) * 2009-08-21 2012-10-03 吉联亚生物科技有限公司 治疗方法和组合物
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays

Also Published As

Publication number Publication date
JP2013506005A (ja) 2013-02-21
CA2775877A1 (en) 2011-04-07
WO2011041309A1 (en) 2011-04-07
RU2012117896A (ru) 2013-11-10
BR112012007114A2 (pt) 2016-07-05
CN102711753A (zh) 2012-10-03
US20110076285A1 (en) 2011-03-31
EP2482814A1 (en) 2012-08-08
AU2010300813A1 (en) 2012-04-26
KR20120091146A (ko) 2012-08-17
EP2482814A4 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
MX2012003759A (es) Metodos y composiciones para tratamiento de fibrosis ocular.
MX2011008296A (es) Metodos y composiciones para el tratamiento de neovascularizacion.
WO2010127152A3 (en) Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
WO2009070693A3 (en) Modulators of ocular oxidative stress
WO2011087548A3 (en) Therapeutic compositions and methods for targeted delivery of active agents
WO2008076556A3 (en) Generation of inner ear cells
WO2010080769A3 (en) Chemotherapeutic methods and compositions
WO2009115557A3 (en) Fungicide hydroximoyl-tetrazole derivatives
MX2010007677A (es) Derivados de hidroximoil-tetrazol como fungicidas.
EP4413994A3 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
MX364441B (es) Composiciones de povidona-yodo oftalmicas no irritantes.
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
WO2009024677A3 (fr) Utilisation d ' acide hyaluronique pour la preparation de compositions destinees a l' amelioration de la fonction de protection de la peau, de l' oeil et des muqueuses
MX2007008790A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
EA201170703A1 (ru) Производные адамантилбензамида
MY147949A (en) Hydrogenated benzo[c]thiophene derivatives as immunomodulators
MX2009003378A (es) Concentrados en suspension para la mejora de la absorcion por la raiz de principios activos agroquimicos.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MY159035A (en) Control agent for soft rot and control method for the same
WO2010062762A3 (en) Compositions and methods for reducing the signs of aging of the skin
TW200942524A (en) Novel aminomethyl benzene derivatives
MX2012012941A (es) Nuevas composiciones oftalmicas.
TW200942530A (en) Pyridine compounds
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2010118291A3 (en) Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal